Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Felzartamab on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Felzartamab is an antibody medicine for multiple myeloma, a cancer of the plasma cells in the bone marrow. In China it is sold as 境斐® (注射用菲泽妥单抗). It was first created by MorphoSys, developed for China by TJ Biopharma, and is now marketed in China by Biogen, with TJ Biopharma making it at its plant in Hangzhou.
China's National Medical Products Administration (NMPA) approved it in August 2026, its first approval anywhere in the world, for adults with:
It is a prescription blood cancer medicine, given in hospital under a haematologist or oncologist.
Myeloma cells carry large amounts of a surface protein called CD38. Felzartamab is a human monoclonal antibody that sticks to CD38 and flags the myeloma cells so that the immune system's killer cells and scavenger cells destroy them. It was designed to make little use of a third route, called complement, which researchers link to infusion reactions. The company reports low and mild infusion reactions and an infusion time of about 1.5 hours.
The phase 3 trial (NCT03952091), published in The Lancet Haematology in 2026, was run at 41 hospitals in China. It included 295 adults whose myeloma had come back after at least one treatment and was not resistant to lenalidomide. Adding felzartamab to lenalidomide and dexamethasone:
In the trial, felzartamab was given as a drip into a vein at 16 mg per kg of body weight on this schedule:
Alongside it, patients took lenalidomide 25 mg by mouth on days 1 to 21 of each 28-day cycle and dexamethasone once a week (40 mg, or 20 mg for people over 75). It is supplied as a powder for injection that is made up and diluted before the drip. Your haematologist sets the exact plan.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Blood counts: low blood counts were the most common severe side effects. In the phase 3 trial, severe (grade 3–4) neutropenia occurred in 55% of patients on the felzartamab combination against 23% on lenalidomide and dexamethasone alone, with low lymphocytes in 41% vs 15%, low white cells in 39% vs 11% and low platelets in 26% vs 11%. Blood counts are checked regularly.
Overall: deaths judged to be related to treatment occurred in 6% of patients on the felzartamab combination and 2% on the comparison treatment, mostly linked to infections or of unknown cause. Safety in pregnancy, breastfeeding and children has not been established in the published data.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For other import options in relapsed myeloma, see our pages on Talvey and Elrexfio.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The vials travel in their sealed original packs under temperature-controlled shipping, kept as directed on the pack all the way to the hospital. Because the dose depends on body weight and the drips are frequent in the first 12 weeks, we plan quantities with the hospital phase by phase. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital on a valid specialist's prescription.
Major myeloma centres here treat patients from across North India, and our New Delhi dispatch point keeps transit to the hospital short.
Vials are delivered to the hospital pharmacy ahead of the two doses in week 1.
Haematologists in Bangalore can request the medicine for a named patient, with the quote shared before anything is ordered.
A long-standing referral hub for myeloma care in South India, used to handling imported infusion medicines.
We schedule deliveries around the weekly drips of the first three months.
Shipments to Kolkata and the eastern states are packed to stay within the labelled storage conditions throughout.
Patients in Pune can use the same documented import route, with updates at each stage.
The treating haematologist can send us the prescription, body weight and treatment history to begin the import.
Patients treated at hospitals in Vellore can have each phase's supply delivered directly to the day-care unit.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating hospital.
We coordinate delivery to public and private cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive the medicine at their hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
